---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Second-generation antipsychotic augmentation"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Second-generation antipsychotic augmentation. Topics: CANMAT guideline: line of treatment for adjunctive atypical antipsychotics, CANMAT guideline: adverse effects and duration of adjunctive treatment, NICE guideline: antipsychotic augmentation and monitoring, VA/DoD guideline: approved agents and adverse effects of augmentation, and 16 further topics. 20 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/second-generation-antipsychotic-augmentation"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Second-generation antipsychotic augmentation

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Second-generation Antipsychotic Augmentation

<a id="topic-2.2.2.1.2-1"></a>

### CANMAT guideline: line of treatment for adjunctive atypical antipsychotics

> “Adjunctive treatment with serotonin-dopamine activity modulators (also known as atypical antipsychotic agents) has the most consistent evidence for efficacy in DTD (Table 7.2).”
> “Aripiprazole and brexpiprazole are listed as first-line agents because of their efficacy and tolerability profile. Cariprazine is recommended as the second-line because there are fewer studies compared to the other agents.”
> “Some agents with Level 1 evidence for efficacy are recommended as second-line treatments because of the increased risk of certain side effects, including olanzapine (weight gain and metabolic side effects), quetiapine-XR (sedation and metabolic side effects), and risperidone (hyperprolactinemia, sexual side effects, and extrapyramidal symptoms).”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.2-2"></a>

### CANMAT guideline: adverse effects and duration of adjunctive treatment

> “Common side effects with aripiprazole and brexpiprazole include akathisia and weight gain.”
> “There are also potential long-term risks with these medications, such as tardive dyskinesia, although the risk is lower compared to older antipsychotics and is mitigated by the lower dosing used for MDD. In studies of conditions other than MDD, long-term use of these agents in older age may be associated with increased mortality.”
> “Finally, there is little evidence available for maintenance treatment with adjunctive agents, so it is unclear how long adjunctive medications should be continued.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.2-3"></a>

### NICE guideline: antipsychotic augmentation and monitoring

> “combining an antidepressant medication with a second-generation antipsychotic (for example, aripiprazole, olanzapine, quetiapine or risperidone) or lithium”
> “when using an antipsychotic the effects of this on depression, including loss of interest and motivation, should be carefully reviewed.”
> “Before starting an antipsychotic, check the person's baseline pulse and blood pressure, weight, nutritional status, diet, level of physical activity, fasting blood glucose or HbA1c and fasting lipids.”
> “For people with depression who are taking an antipsychotic, consider at each review whether to continue the antipsychotic based on their current physical and mental health risks.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.2-4"></a>

### VA/DoD guideline: approved agents and adverse effects of augmentation

> “Three atypical antipsychotics are FDA-approved for MDD as adjunctive treatment/augmentation: aripiprazole, brexpiprazole, and quetiapine-XR.”
> “Olanzapine is approved for the treatment of acute treatment-resistant MDD when used in combination with fluoxetine, but olanzapine by itself is not indicated for the treatment of treatment-resistant depression (TRD).”
> “Fair quality evidence found that compared to placebo, aripiprazole had a significantly higher incidence of akathisia and weight gain; olanzapine had a significantly higher incidence of weight gain and sedation; quetiapine had significantly greater weight gain and sedation; and risperidone had greater, but not statistically significant, weight gain when compared to antidepressants plus placebo.”
> “Due to the possibility of additional side effects and the potential for drug-drug interactions with augmentation, SGAs require appropriate monitoring (e.g., glucose, complete blood count, hepatic panel, lipid panel, body mass index, waist circumference, blood pressure, involuntary movements/tardive dyskinesia, slit lamp exam [quetiapine-only]).”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Aripiprazole label: indication, boxed warning, and adjunctive efficacy

> “Adjunctive Treatment of Major Depressive Disorder (14.3)”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants.”
> “In the two trials (n=381, n=362), ABILIFY was superior to placebo in reducing mean MADRS total scores (Studies 1, 2 in Table 25).”
> “The mean final dose at the end point for the two trials was 10.7 and 11.4 mg/day.”

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### Aripiprazole label: change in MADRS total score at week 6

| Study | Placebo-subtracted difference in MADRS change (95% CI) |
| --- | --- |
| Study 1 | “-2.84 (-4.53, -1.15)” |
| Study 2 | “-3.01 (-4.66, -1.37)” |

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

### Aripiprazole label: adverse reactions in adjunctive trials

> “The incidence of discontinuation due to adverse reactions was 6% for patients treated with adjunctive ABILIFY and 2% for patients treated with adjunctive placebo.”
> “The commonly observed adverse reactions associated with the use of adjunctive ABILIFY in patients with major depressive disorder (incidence of 5% or greater and ABILIFY incidence at least twice that for placebo) were: akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.”

Source: [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### Brexpiprazole label: indication, boxed warning, and adjunctive efficacy

> “Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and young adult patients in short-term studies.”
> “In Studies 1 and 2, REXULTI (plus ADT) 2 mg once daily and 3 mg once daily were superior to placebo plus ADT in reducing mean MADRS total scores.”

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

### Brexpiprazole label: change in MADRS total score at week 6

| Study and dose | Placebo-subtracted difference in MADRS change (95% CI) |
| --- | --- |
| Study 1, 2 mg/day | “-3.2 (-4.9, -1.5)” |
| Study 2, 1 mg/day | “-1.3 (-2.7, 0.1)” |
| Study 2, 3 mg/day | “-2.0 (-3.4, -0.5)” |

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-10"></a>

### Brexpiprazole label: adverse reactions in adjunctive trials

> “Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): Weight increased, somnolence, and akathisia (≥5% and at least twice the rate for placebo)”
> “In Studies 1 and 2, among the adverse reactions that occurred at ≥2% incidence in the patients treated with REXULTI plus ADT, the incidences of akathisia and restlessness increased with increases in dose.”

Source: [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)

<a id="topic-2.2.2.1.2-11"></a>

### Quetiapine extended-release label: indication, boxed warning, and adjunctive efficacy

> “Major depressive disorder, adjunctive therapy with antidepressants”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “Increased risk of suicidal thoughts and behavior in children, adolescents and young adults taking antidepressants.”
> “The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in the treatment of MDD was demonstrated in two 6-week placebo-controlled, fixed-dose trials (n=936).”
> “SEROQUEL XR 300 mg once daily as adjunctive treatment to other antidepressant therapy was superior to antidepressant alone in reduction of MADRS total score in both trials. SEROQUEL XR 150 mg once daily as adjunctive treatment was superior to antidepressant therapy alone in reduction of MADRS total score in one trial”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.2-12"></a>

### Quetiapine extended-release label: adverse reactions and metabolic warnings

> “Most common adverse reactions (incidence ≥5% and twice placebo): Adults: somnolence, dry mouth, constipation, dizziness, increased appetite, dyspepsia, weight gain, fatigue, dysarthria, and nasal congestion”
> “Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.2-13"></a>

### Cariprazine label: indication, boxed warning, and adjunctive efficacy

> “Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “VRAYLAR 1.5 mg + ADT was superior to placebo + ADT at end of Week 6 on the MADRS total score. The treatment effect in the VRAYLAR 3 mg per day + ADT group (vs. placebo + ADT) was not statistically significant.”
> “VRAYLAR 2 to 4.5 mg (mean dose was 2.6 mg) + ADT was superior to placebo + ADT at end of Week 8 on the MADRS total score. The treatment effect in the VRAYLAR 1 to 2 mg per day + ADT group (vs. placebo + ADT) was not statistically significant.”

Source: [Vraylar prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204370s014s015s016s017lbl.pdf)

<a id="topic-2.2.2.1.2-14"></a>

### Cariprazine label: adverse reactions in adjunctive trials

> “Adjunctive treatment of MDD: akathisia, restlessness, fatigue, constipation, nausea, insomnia, increased appetite, dizziness, and extrapyramidal symptoms”

Source: [Vraylar prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204370s014s015s016s017lbl.pdf)

<a id="topic-2.2.2.1.2-15"></a>

### Olanzapine and fluoxetine label: treatment-resistant depression indication and efficacy

> “Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode)”
> “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
> “The efficacy of SYMBYAX in acute treatment resistant depression was demonstrated with data from 3 clinical studies (n=579) in adults (18 to 85 years).”
> “Results from this study yielded statistically significant greater reduction in mean total MADRS scores from baseline to endpoint for SYMBYAX versus fluoxetine and olanzapine.”

Source: [Symbyax prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021520s056lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

### Olanzapine and fluoxetine label: adverse reactions and weight gain

> “Most common adverse reactions (≥5% and at least twice that for placebo) in adults: sedation, weight increased, appetite increased, dry mouth, fatigue, edema, tremor, disturbance in attention, blurred vision.”
> “In an analysis of 7 controlled clinical studies, 2 of which were placebo-controlled, the mean weight increase for SYMBYAX-treated patients was greater than placebo-treated patients [4 kg (8.8 lb) vs -0.3 kg (-0.7 lb)]. Twenty-two percent of SYMBYAX-treated patients gained at least 7% of their baseline weight, with a median exposure to event of 6 weeks.”

Source: [Symbyax prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021520s056lbl.pdf)

<a id="topic-2.2.2.1.2-17"></a>

### Network meta-analysis of augmentation agents: response, remission, and discontinuation

> “A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA.”
> “For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates.”
> “In order of efficacy, T4, aripiprazole, risperidone, quetiapine, olanzapine(fluoxetine), brexpiprazole were statistically significant compared to placebo with RRs ranging from 1.44 (1.00–2.08) for brexpiprazole to 1.91 (1.04–3.52) for T4.”

Source: [Nuñez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328668/)

<a id="topic-2.2.2.1.2-18"></a>

### Meta-analysis of adjunctive atypical antipsychotics: remission, response, and harms

> “All four drugs had statistically significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug.”
> “On measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on quality of life (g = 0.49).”
> “Adjunctive aripiprazole was frequently associated with akathisia (NNH, 4; 95% CI, 3–6) and also linked to a statistically significant elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33) and significant weight gain of ≥7% during trials (NNH, 29; 95% CI, 10–119).”
> “Adjunctive quetiapine had a very high rate of reported sedation (NNH, 3; 95% CI, 2–3)”

Source: [Spielmans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3595214/)

<a id="topic-2.2.2.1.2-19"></a>

### Aripiprazole augmentation in veterans: response and adverse effects

> “Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).”
> “Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain.”
> “Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.”

Source: [Mohamed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817471/)

<a id="topic-2.2.2.1.2-20"></a>

### Aripiprazole augmentation in adults aged 60 years or older: well-being and falls

> “The difference in the change from baseline in psychological well-being between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02)”
> “In step 1, fall rates during the acute phase over a period of approximately 10 weeks were 0.33 per patient in the aripiprazole-augmentation group, 0.55 in the bupropion-augmentation group, and 0.38 in the switch-to-bupropion group (Table 3).”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
